WuXi group wrestles with uncertainty over pharma tariffs
Drugs services giant WuXi AppTec cashed in a stake in Wuxi XDC to soften the blow from a first round of Trump tariffs, as the pharma sector braces for another…
BRIEF: WuXi XDC’s revenue, profit jump in 2024
WuXi XDC Cayman Inc. (2268.HK), a provider of contract services for drug companies, said on Wednesday its revenue and profit rose sharply last year on strong demand for services related…
U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
The latest draft of a U.S. biosecurity law would give drug companies until 2032 to cut their ties with Chinese contract suppliers, allowing WuXi companies time to focus on Europe…
Potential U.S. targeting casts shadow over WuXi AppTec family
Proposed U.S. legislation could ban federal agencies and federally funded institutions from buying devices and services from Chinese biotech companies Key Takeaways: WuXi AppTec, which could be banned from doing…
FAST NEWS: WuXi XDC’s profit surges on growth in ADC market
The latest: WuXi XDC Cayman Inc. (2268.HK) announced Thursday that it expects to report its net profit last year jumped more than 80% from 2022, while its adjusted net profit and…
WuXi Bio prescribes share buyback to relieve revenue pain
The pharma services provider has shocked investors with a steep downward revision of its earnings outlook, slashing its full-year revenue growth forecast to just 10% from an initial 30% and…
FAST NEWS: WuXi XDC kicks off IPO with star cornerstone investors
The latest: WuXi XDC Cayman Inc. (2268.HK), a unit of WuXi Biologics (Cayman) Inc. (2269.HK), formally launched its initial public offering on Tuesday, with plans to raise up to HK$3.68…
Recent Articles
U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
2269.HK
2359.HK
2268.HK
Potential U.S. targeting casts shadow over WuXi AppTec family
2359.HK
603259.SHG
